P1.01-52 BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC

杜瓦卢马布 银耳霉素 医学 肿瘤科 培美曲塞 内科学 临床终点 化疗 实体瘤疗效评价标准 肺癌 癌症 免疫疗法 彭布罗利珠单抗 进行性疾病 随机对照试验 顺铂 易普利姆玛
作者
S. Kulkarni,Scott A. Laurie,Glenwood Goss,Franco Perrone,Brett Hughes,Nick Pavlakis,Martin R. Stockler,Anne‐Sophie Blais,L. Zibdawi,F. Vera – Badillo,Natasha B. Leighl
出处
期刊:Journal of Thoracic Oncology [Elsevier]
卷期号:13 (10): S480-S481 被引量:3
标识
DOI:10.1016/j.jtho.2018.08.608
摘要

Immunotherapy improves survival of patients with non-small cell lung cancer (NSCLC). Current clinical trials are studying various combinations of PD-1/PD-L1 inhibitors and CTLA-4 agents with or without chemotherapy, to enhance treatment efficacy. This trial will determine the effects of adding platinum chemotherapy to combination of check point blockade with durvalumab and tremelimumab in the first line treatment of advanced non-small cell lung cancer. BR-34 is a CCTG led randomized proof-of-concept trial of durvalumab and tremelimumab, with or without platinum-based chemotherapy in patients with metastatic squamous or non-squamous NSCLC. Patients who have histologically confirmed Stage IV NSCLC and wild type EGFR and ALK, PDL-1 unselected, with measurable disease by RECIST 1.1, and available tissue for biomarker testing are eligible and are stratified by stage, histology and smoking status. Primary end point is overall survival. Secondary end points include progression free survival at 1 year, overall response rate, quality of life, cost effectiveness and correlative studies on tissue and blood (including PD-L1, tumour mutation burden and cell-free DNA) with outcomes and response, and PFS by iRECIST (exploratory). In total 300 patients will be recruited from Canada, Australia and Italy. Arm A will receive 4 cycles of fixed doses of tremelimumab (T) 75 mg plus durvalumab (D) 1500 mg every 28 days IV, followed by durvalumab (D) maintenance and Arm B will receive standard platinum-doublet chemotherapy in combination with T+D every 21 days for 4 cycles, followed by maintenance D (with pemetrexed for those with non-squamous histology), until progression. BR-34 was initiated in February 2017 in Canada and total 150 patients have been randomized as of April 2018, including 137 from Canada and 13 from Australia. 28 sites are open to accrual in Canada, 15 in Australia the trial will soon be opened in Italy. At the current rate of accrual, the CCTG BR-34 trial should be fully accrued by Q1 2019. This is the first randomized trial of combination checkpoint blockade +/- platinum-doublet chemotherapy in advanced non-small cell lung cancer. Acknowledgements: BR-34 is an academic, co-operative group trial led by Canadian Cancer Trials Group (CCTG) in collaboration with ALTG and NHMRC Clinical Trials Centre, with support from AstraZeneca and Canadian cancer society. NCT03057106
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yuuta完成签到,获得积分20
刚刚
刚刚
无花果应助嘉人采纳,获得10
1秒前
脑洞疼应助苏唱采纳,获得10
1秒前
1秒前
田様应助snowskating采纳,获得10
2秒前
2秒前
传奇3应助zhenxing采纳,获得10
2秒前
Linn完成签到,获得积分10
2秒前
林波er发布了新的文献求助10
3秒前
深情安青应助why采纳,获得10
3秒前
研友_VZG7GZ应助韭菜盒子采纳,获得10
4秒前
4秒前
paparazzi221应助枫溪采纳,获得100
5秒前
6秒前
坚定冬易发布了新的文献求助10
8秒前
大个应助牛司采纳,获得10
8秒前
8秒前
9秒前
9秒前
不安的觅风关注了科研通微信公众号
9秒前
10秒前
和和完成签到,获得积分10
10秒前
跳跃的猹完成签到 ,获得积分10
11秒前
11秒前
wkjfh应助哒哒哒采纳,获得10
12秒前
XIXIw完成签到 ,获得积分10
12秒前
tianzml0应助冉海琳采纳,获得10
12秒前
林波er完成签到,获得积分10
13秒前
多发文章早毕业完成签到 ,获得积分10
13秒前
XLXY驳回了沐白应助
14秒前
leyellows发布了新的文献求助10
14秒前
anyycui完成签到,获得积分10
14秒前
liushuai完成签到 ,获得积分10
15秒前
Chirstina完成签到,获得积分10
16秒前
liu发布了新的文献求助10
16秒前
TIANYIN完成签到,获得积分10
16秒前
pluto应助李伟采纳,获得10
17秒前
17秒前
我是老大应助Raydiaz采纳,获得10
20秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
【本贴是提醒信息,请勿应助】请在求助之前详细阅读求助说明!!!! 20000
Evolution 4000
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
La Chine révolutionnaire d'aujourd'hui / Van Min, Kang Hsin 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3037169
求助须知:如何正确求助?哪些是违规求助? 2696126
关于积分的说明 7355236
捐赠科研通 2337975
什么是DOI,文献DOI怎么找? 1237439
科研通“疑难数据库(出版商)”最低求助积分说明 602481
版权声明 595006